FDA-Approved Indications for Escitalopram
Escitalopram is FDA-approved for two primary indications: (1) acute and maintenance treatment of major depressive disorder in adults and adolescents aged 12-17 years, and (2) acute treatment of generalized anxiety disorder in adults 1.
Primary Indications
Major Depressive Disorder (MDD)
- Adults: Approved for both acute treatment and long-term maintenance therapy
- Adolescents (12-17 years): Approved for acute and maintenance treatment 1
- MDD diagnosis requires a prominent depressed or dysphoric mood lasting nearly every day for at least 2 weeks, with at least 5 of 9 DSM criteria including: depressed mood, anhedonia, significant weight/appetite changes, sleep disturbance, psychomotor changes, fatigue, guilt/worthlessness, concentration difficulties, or suicidal ideation 1
Generalized Anxiety Disorder (GAD)
- Adults only: Approved for acute treatment 1
- GAD diagnosis requires excessive anxiety and worry persistent for at least 6 months, difficult to control, with at least 3 associated symptoms: restlessness, easy fatigue, concentration difficulty, irritability, muscle tension, or sleep disturbance 1
Additional Approved Indications (Regional)
In the European Union, escitalopram has broader approval beyond the US indications, including:
These anxiety disorder indications are supported by 8-12 week randomized, placebo-controlled trials showing consistent efficacy across all parameters 4.
Dosing Framework
- Standard adult dose: 10-20 mg/day 5
- Adolescent dose: Same as adults (10-20 mg/day) 6
- Elderly patients: 10 mg/day maximum due to 50% increase in AUC and half-life 1
- Hepatic impairment: 10 mg/day maximum 1
- Renal impairment: No adjustment needed for mild-to-moderate impairment; use caution in severe impairment 1
Clinical Context
Escitalopram is considered a preferred first-line agent for depression alongside citalopram, bupropion, mirtazapine, venlafaxine, and sertraline due to favorable adverse effect profiles 5. Guidelines show no clinically significant differences in efficacy among second-generation antidepressants for MDD, though escitalopram demonstrates modest statistical superiority over citalopram (relative benefit 1.14, CI 1.04-1.26) 7. This advantage is more apparent in patients with greater symptom severity 8.
Important Caveats
- Treatment duration: Continue for 4-12 months after first MDD episode; patients with recurrent depression may benefit from prolonged treatment 5
- Adolescent use: Escitalopram is only the second antidepressant approved for adolescent MDD in the US 6
- Off-label anxiety uses in US: While panic disorder, social anxiety disorder, and OCD are approved in Europe, these remain off-label in the United States despite supporting evidence 2, 4